Fabhalta (iptacopan) was approved by UK drugs regulator the MHRA last month, becoming an option for an estimated 220 out of ...

Travere Therapeutics TVTX announced that the FDA granted full approval to its oral non-immunosuppressive drug Filspari ...

In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Analysts at Jefferies in a note dated Tuesday have lowered their rating for Novartis (SIX:NOVN) (NYSE:NVS) to "hold” from ...

The news comes as NICE marks its 1000th medicine evaluation since April 1999 when it formed. Of the appraisals, more than ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.